The Blinder-Oaxaca (BO) decomposition helps to identify the causes of disparity between two groups based on observed characteristics, and quantifies the residual disparity due to unobserved heterogeneity. This study uses the nonlinear BO decomposition, an extension of the original BO decomposition, to identify and quantify the observed causes behind the racial/ethnic disparity in antiobesity medication use among US adults who met the medical criteria to receive these medications. METHODS: The Medical Expenditure Panel Survey data, 2002Survey data, -2007, was used in this retrospective cross-sectional study. The medical criteria was defined as adults (ageϾϭ20 years) with body mass index (BMI)Ͼ30, or with BMIՆ27 and comorbidities such as hypertension, cardiovascular diseases, diabetes or hyperlipidemia. The non-linear BO decomposition method was used to identify the contribution of each observed socio-demographic and health characteristic in explaining the racial/ethnic disparity and to estimate the residual unexplained disparity. RESULTS: A total of 395,319,750 adults met medical criteria from 2002-2007; of which, 0.61% used anti-obesity medications. The proportion of medically eligible Blacks using anti-obesity medication was 33% lower than Whites. The nonlinear BO decomposition method revealed that only marital status explained the racial/ethnic disparity among the observed characteristics. Blacks were younger, had a higher proportion of women in the sample, and had a higher BMI, and these characteristics were the chief determinants of increased anti-obesity medication use. Thus, the decomposition estimated that if the blacks had similar characteristics as the whites the observed disparity in the sample would have been 58% higher. CONCLUSIONS: The decomposition revealed interesting but disconcerting findings. None of the differences in the observed socio-demographic and health characteristics (except marital status) successfully explained the racial disparity. Thus, further exploratory studies examining racial differences in individual beliefs, behavioral patterns and provider prescription patterns are vital to understand these disparities.
OBJECTIVES:
The US ranks first among all developed countries for obesity/overweight prevalence. Anti-obesity medications may help address this public health problem, but national utilization data for anti-obesity medications is lacking. The study objective was to examine trends in anti-obesity medication use among adults who met medical criteria (MC) and understand the extent of use of such medications among adults who did not meet MC. METHODS: A retrospective crosssectional study was performed using the Medical Expenditure Panel Survey data from [2002] [2003] [2004] [2005] [2006] [2007] . The study comprised all non-pregnant adults (Ն20 years of age; Nϭ210, 829, 728) . Meeting the MC for anti-obesity medication use for an individual was defined as having Body Mass Index (BMI) Ͼ 30 (clinically obese) or having BMI Ն 27 with comorbidities such as hypertension, cardiovascular disease, diabetes and hyperlipidemia. Anti-obesity medications were identified from prescription medicine files using national drug codes and drug names. Proportions of antiobesity medication users among adults who met MC were calculated for each year and logistic regression was performed to test utilization trends. Descriptive analysis was conducted to assess proportion of adults using anti-obesity medications who did not meet MC. RESULTS: Of the adults who met MC (Nϭ65, 886, 625) , 0.52% were taking anti-obesity medications. Analysis of multiyear data showed no statistically significant trend (p-value ϭ 0.25) in anti-obesity medication use among adults who met MC from 2002 to 2007. Of all US adults who were taking anti-obesity medications (Nϭ542,297), 31.98% did not meet MC for use. CONCLUSIONS: Less than one percent of eligible adults used anti-obesity drugs in each year and antiobesity medication use did not change from 2002 to 2007. Almost one third of anti-obesity medication users did not meet MC. Given the associated side-effects for these medications, further research is needed to understand the use of antiobesity medications among adults who do not meet MC. 
PSY56 CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION DRUG MONITORING PROGRAMS

OBJECTIVES:
Studies have shown that despite the national guidelines recommending counseling for obese patients, counseling rates during outpatient visits remain low. We determined the trends for obesity counseling (diet, exercise and weight reduction) from year 2005 to 2008 and the association between being clinically diagnosed with obesity and being counseled, for obese adults during their outpatient visits. We also determined if clinical diagnosis of obesity varied with obesity class which is classified by BMI. METHODS: We used the data from 2005 to 2008 National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS). The study included all adults having Body Mass Index (BMI) Ն 30. The outcome of interest was whether the patient received obesity counseling or not. RESULTS: 478 million patients had BMI Ն 30 of which only 6% were clinically diagnosed with obesity, and 31% received counseling. There was no statistically significant change in counseling for obese adults from the year 2005 to 2008. Patients clinically diagnosed with obesity had 7.7 times (95% CI: 5.3-11.1) greater odds of receiving counseling as compared to undiagnosed obese patients after controlling for sociodemographic and clinical factors. Moreover, class II (35.5 Յ BMI Յ39.9) and class III (BMI Ն40) obese patients had 1.8 (95% CI: 1.4-2.4) and 4.5 (95% CI: 3.4-6.0) times greater odds of being diagnosed with obesity as compared to class I (30 ՅBMI Յ 34.4) obese patients. CONCLUSIONS: Being clinically diagnosed with obesity is an indicator of access to care, and the patient's initiatives to seek obesity-related care. Our finding of low rates of counseling for diet, exercise or weight reduction during visits by obese patients indicates that obesity is commonly under-diagnosed. Interventions should focus on patient awareness strategies to increase the rate of clinical diagnosis and hence counseling.
PSY58 DISPARITY IN OBESITY MANAGEMENT: UNDER-TREATMENT AMONG ELDERLY POPULATION
Shah AJ, Patel JG, Rajan SS, Abughosh S, Masilamani S University of Houston, Houston, TX, USA OBJECTIVES: Obesity is a major cause of morbidity and mortality and a rising epidemic worldwide. Despite guideline recommendations, many obese patients fail to receive adequate medical care. The objectives of the study were to examine predictors of obesity treatment and assess differences in receiving treatment between various age groups. METHODS: The study used data from 2006-2008 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. Adults with age Ն 20 years were included and obesity was defined as having a BMI Ն 30. Obesity treatment was defined as the receipt of medication (like Sibutramine, Orlistat, etc.) and/or obesity counseling in terms of weight reduction, exercise, or diet counseling. Splines were constructed to assess changes in obesity treatment with age. Descriptive statistics and multivariate logistic regression were used to determine predictors of receiving obesity treatment. RESULTS: Out of 3.1 billion visits, 29.2% (95%CI:28.1-30.3%) were obese. Among those, 31.4% (95%CI: 28.2-34.6%) between ages 20-39; 32.5% (95%CI:29.6 -35.4%) between ages 40-64 and 25.4% (95%CI:22.2-28.7%) above 64 years received treatment. In multivariate model, a unit increase in age increased the likelihood to receive treatment by 1.8% (95%CI: 0.1-3.6%) within the age group 20-39 years; decreased the likelihood by 1.4% (95%CI: 2.3-0.4%) within 40-64 years; and decreased the likelihood by 3.4% (95%CI:5.0 -1.7%) above 64 years. Primary care physicians (OR-1.66, 95%CI:1.38-1.99), were approximately 70% more likely to provide treatment compared to specialists. Individuals with comorbidities were more likely to receive treatment (OR-1.37, 95% CI:1.17-1.60). A significant difference across geographical region was also observed. CONCLUSIONS: Study suggests differences in obesity management across age groups. Older adults were less likely to receive obesity treatment. Further research is needed to ensure that quality care is provided across all age groups.
PSY59 IMPACT OF OBESITY ON AGE-SPECIFIC PREVALENCE OF CHRONIC DISEASES IN THE UNITED STATES
taking ratios of predicted prevalence rates for obese versus non-obese individuals. Bootstrapped 95% confidence intervals were generated for prevalence ratios. RESULTS: Among obese adults the unadjusted prevalence of hypertension was (34.40%), followed by dyslipidemia (21.87%), diabetes (16.34%) and asthma (6.92%). Adjusted prevalence of chronic diseases was always higher among obese as compared to non-obese and the entire population. The prevalence ratio for diabetes was 3.06 (95% C.I: 2.82 -3.30) at the age of 20 and was 2.20 (95% C.I: 2.09 -2.31) at 70 years. At any age, obesity increases the likelihood of these conditions by at least 50% as compared to non-obese individuals. CONCLUSIONS: Prevalence ratios indicate that obesity has highest impact on prevalence of diabetes; followed by hypertension, osteoarthritis, dyslipidemia. Study findings suggest that obesity is not only a disease, but may also be a cause for other chronic disorders. There is a need to develop effective interventions to combat obesity and thus minimize its impact on other diseases in the United States. OBJECTIVES: Adherence to Food and Drug Administration recommended administration with adalimumab, etanercept, or infliximab may be variable. Suboptimal adherence patterns may contribute to health care cost increases. This study estimated incremental health care costs of tumor necrosis factor inhibitor (anti-TNF) under-utilization from a managed care perspective. METHODS: Medical/pharmacy claims from the LifeLink™ Health Plan database were used. Inclusion criteria included: index anti-TNF started January 1, 2004-December 31, 2007, age Ն18 years, 2 pre-index rheumatoid arthritis diagnosis codes (ICD-9 code 714.xx), Ն365 days of index drug, continuous enrollment 6/12 months pre-/post-index. Exclusion criteria included: switching biologics post-index and selected inflammatory conditions. Under-utilization events were defined as prescriptions/infusions with 10% less than recommended dosing for adalimumab (40 mg every other week/weekly with/ without methotrexate), etanercept (50 mg weekly), or infliximab (3 mg/kg dose and maintenance infusion interval Ͼ 56 days). Incremental increases in health care costs for patients with under-utilization, compared to receiving recommended dosing, were estimated using cost regression models controlling for refill/infusion intervals. Models were estimated for a 12-month time horizon and until index drug discontinuation or loss of enrollment. RESULTS: A total of 4,586 RA patients receiving adalimumab (Nϭ1,255; 27,540 prescriptions), etanercept (Nϭ2,242; 48,517 prescriptions), or infliximab (Nϭ1,089; 19,656 infusions) were included. Mean lengths of time (days) patients received adalimumab (856), etanercept (881), and infliximab (903) were comparable. Proportion of under-utilization events were 16%, 39%, and 2% for adalimumab, etanercept, and infliximab, respectively. Adalimumab or etanercept under-utilization was significantly associated with incremental increased health care costs ($2,352 and $879; pϽ0.01) for 12 months and through end of data ($4,677 and $3,806; pϽ0.01). Infliximab under-utilization was infrequent and not associated with increased health care costs. CONCLUSIONS: In this analysis, adalimumab or etanercept under-utilization was associated with increased total healthcare costs; however, infliximab under-utilization did not have a similar result. Additional research assessing clinical consequences of under-utilization is warranted. 
PSY60 ECONOMIC CONSEQUENCES OF UNDER-UTILIZATION WITH TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS
PSY61 CHARACTERISTICS OF GOLIMUMAB UTILIZATION AND COSTS IN A SPECIALTY PHARMACY PROVIDER (SPP) SETTING
OBJECTIVES:
Golimumab is a 50 milligram (mg), once monthly, injected anti-tumor necrosis factor alpha therapy for treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. This study calculated expected costs of annual golimumab therapy based upon observed dosing patterns within a SPP population during the first 16 months of golimumab availability. METHODS: Pharmacy and corresponding eNAVIGATOR TM patient care management data were collected by Diplomat Specialty Pharmacy, Flint, MI for adult patients with a golimumab prescription between 4/24/2009 and 8/24/2010. Data were analyzed statistically and are reported as n, %, meanϮstandard deviation (SD) and median. Costs were modeled in US dollars using the wholesale acquisition cost (WAC; effective 6/9/2010) of $1,731.48 per 50 mg. RESULTS: The study included 89 patients. The majority were female (65%); age Ͼ45 years (69%); and reported prior biologic use (56%). A 50 mg golimumab dose was dispensed in 100% of patients and 100% of all doses. The mean (ϮSD) interval between golimumab doses was 32.0 Ϯ14.1 days and the median was 28 days. The mean golimumab dosing interval in patients reporting biologic use prior to golimumab initiation was 32.9Ϯ15.9 days (meanϮSD) and was similar to the mean dosing interval observed in patients reporting no biologic use prior to golimumab initiation (meanϮSD: 31.1Ϯ12.1 days; pϭ0.15; NS). Based upon modeling of these early observations, the average golimumab patient will utilize approximately 11.4 doses of golimumab annually at a cost of $19,739 (WAC).
CONCLUSIONS:
In this SPP population, all patients received 50 mg of golimumab. The mean and median times between distribution of golimumab doses were 32 days and 28 days, respectively. Based upon the dosing and distribution patterns observed, the estimated average annual per patient cost of golimumab would be $19,739. Golimumab utilization may be similar for patients regardless of prior use of biologic therapies. 
PSY62 PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS
OBJECTIVES:
To identify perceived benefits and disadvantages of intravenous infusion (IV) biologic therapy among patients with immunology conditions currently treated with IV biologic medication. METHODS: Semi-structured telephone interviews were conducted with patients self-reporting a diagnosis of ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, or ulcerative colitis and currently receiving IV biologic therapy. Study protocol and questionnaire were approved by an independent institutional review board. Patients rated satisfaction with current IV medication on a 7-point Likert scale, where 1ϭ not at all satisfied and 7ϭvery satisfied. Patients also discussed benefits and disadvantages of IV biologic therapy and reasons for IV preference. RESULTS: 405 interviews were conducted. Mean satisfaction was 6.1; 77% rated satisfaction as 6 or 7. The most frequently described benefits of IV therapy related to healthcare professional monitoring and oversight at time of infusion. More than half of patients also experience a social benefit of IV administration, including talking to other patients about experiences (56%) and tying-in other activities with infusion facility visits (55%). Most commonly described disadvantages of infusion were duration of infusion (41%) and scheduling issues (23%). Of current IV users, most (82%, nϭ332) prefer an IV medication to a subcutaneous injection. The most common reasons for IV preference were: not wanting to self-inject (43%), less frequent dosing (34%), and preference for healthcare professional administration (24%). Satisfaction with medication and perceived benefits varied somewhat by demographics, immunologic condition, and factors related to treatment. CONCLUSIONS: Current IV biologic users are highly satisfied with their medications. Patients perceive the additional opportunity for healthcare provider interaction at infusion facilities as a benefit of this mode of administration. These results support the need for continued patient access to IV therapeutic options and shared decision-making between patients and physicians when selecting biologic treatment. OBJECTIVES: Infliximab (IFX) is an infusible anti-tumor necrosis factor (anti-TNF) drug used in the treatment of rheumatoid arthritis (RA), with Food and Drug Administration (FDA) recommended administrations of 3 mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter. Dose increases up to 10 mg/kg or decreases in infusion intervals to every 4 weeks may be appropriate based on individual response. Limited data are available presenting weight-based dosing, total quantity administered, and infusion intervals simultaneously over the course of 30 infusions. The objective of this study was to calculate weight-based dosing, total quantity infused, and infusion intervals for RA patients receiving IFX. METHODS: An event-level analysis was conducted using medical/pharmacy claims from the IMS LifeLink™ Health Plan database. Inclusion criteria included: IFX initiation January 1, 2004-December 31, 2007 (i.e., index date); patient age Ն18 years old; 2 RA diagnosis codes (ICD-9 714.xx); and 365 days of IFX persistence (i.e., number of days between first and last IFX treatment). Patients were excluded if they had: psoriatic arthritis (ICD-9 696.0), psoriasis (ICD-9 696.1), ulcerative colitis (ICD-9 556.xx), Crohn's disease (ICD-9 555.xx), or ankylosing spondylitis (ICD-9 720.0); evidence of any anti-TNF during the 6 months prior to index date; or evidence of taking abatacept or rituximab while on IFX. RESULTS: There were 19,656 IFX infusion events (Nϭ1,089) identified. The median weight-based doses spanned 3.0-4.2 mg/kg. Overall median quantity infused at each infusion spanned 330-477 mg. Median infusion intervals spanned 50-56 days for infusions 4-20. The median infusion intervals spanned 44-50 days for infusions 21-30. CONCLUSIONS: The observed IFX administration schedule was consistent with FDA-approved prescribing of weight-based dosing and infusion intervals over the course of 30 infusions. These data contribute to the published literature by describing a consistent real-world administration schedule over a longer period of time compared to other published studies. 
PSY63 LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS ACROSS 30 INFUSIONS
PSY64 GE CENTRICITY® ELECTRONIC MEDICAL RECORDS STUDY: COMORBIDITIES AND BIOLOGIC EXPERIENCE AMONG PATIENTS RECEIVING GOLIMUMAB
OBJECTIVES:
Golimumab is the first and only monthly subcutaneous fully human anti-TNF approved in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study evaluated co morbidities and pre-index biologic use among patients who received golimumab in the GE Centricity® electronic medical records (EMR) database. METHODS: Longitudinal EMR data were collected from outpatient practices in the United States. It contains clinical information on over 15 million patients through September 2010. Patients were selected based on the following criteria: Ն1ICD-9 diagnosis of RA, PsA, or AS; Ն18 years of age at the time of the first diagnosis; data 6-months prior and 3-months after a prescription record of the first biologic, and at least one prescription record for golimumab. Biologic experience was defined as use of a biologic within 6 months prior to the first golimumab record. RESULTS: A total of 153 [118 (RA); 20 (PsA); 15 (AS)] patients receiving golimumab were identified as meeting all the inclusion criteria. The mean age was 49 years and 75% were female; 101 (66%) A70 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
